Treating breast implant-associated anaplastic large cell lymphoma.

Each year, hundreds of thousands of women undergo aesthetic or reconstructive breast implant surgery. Clinicians and patients must be aware of the benefits and risks of this surgery. Recently, the FDA suggested a recall of certain textured breast implants because of a link between these implants and a rare form of lymphoma, now referred to as breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). This malignancy has an indolent course and an excellent prognosis when detected and treated early. This article reviews BIA-ALCL, addresses public safety advisories, and emphasizes protocol that all clinicians should follow when encountering a patient with textured breast implants.